Written Question·Department of Health and Social Care·UIN 74361

Trastuzumab Deruxtecan

Tabled: 2 September 2025

Answered: 29 October 2025

Question

Gregory Stafford

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of Enhertu for the treatment of (a) HER2-positive and (b) HER2-low breast cancer.

Answer

Dr Zubir Ahmed

The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an evaluation of a treatment’s...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 74361) →